Alumis is a precision immunology company looking to eliminate the “all comer” approach that is seen with today’s treatments for people with autoimmune disease. Even with innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Alumis leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug discovery, development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $259M
Investors 2
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 01.07.2025 | Omega Fund... | omegafunds... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.03.2024 | Series C | $259M | - |
Mentions in press and media 6
| Date | Title | Description |
| 09.03.2024 | Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting | - |
| 09.03.2024 | Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting | – STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; sustained maximal target inhibition safely achieved at top dose – – Open label extension (OLE) study data to date demonstr... |
| 07.03.2024 | Alumis Raises Upsized $259M Series C Financing | Alumis, a San Francisco, CA-based clinical-stage biopharmaceutical company, raised an upsized $259M Series C funding. The round was led by existing investor Foresite Capital, and new investors, Samsara BioCapital and venBio Partners, with a... |
| 06.03.2024 | Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction | - |
| 06.03.2024 | Alumis closes $259M series C in year's largest private biotech fundraise yet | Alumis has reeled in an eye-watering $259 million series C financing that will support a pipeline of oral therapies designed to tackle immune dysfunction and help launch a phase 3 psoriasis trial for lead asset ESK-001. It marks the biggest... |
| - | Alumis | “We are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases.” |